Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy

被引:60
作者
Melamed, Alexander
Nitecki, Roni
Boruta, David M., II
del Carmen, Marcela G.
Clark, Rachel M.
Growdon, Whitfield B.
Goodman, Annekathryn
Schorge, John O.
Rauh-Hain, J. Alejandro
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol, Boston, MA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
PRIMARY SURGERY; TRIAL;
D O I
10.1097/AOG.0000000000001851
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer. METHODS: We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who underwent neoadjuvant chemotherapy and interval debulking surgery. We compared 3-year overall survival, duration of postoperative hospitalization, 90-day postoperative mortality, and residual disease status between women who underwent interval debulking by laparoscopy and by laparotomy. We used the Kaplan-Meier method and Cox regression models in survival analyses. At a significance of .05, this study had 80% power to detect an 8% difference in 3-year survival. The main analysis was intention to treat. RESULTS: We identified 3,071 women meeting inclusion criteria, of whom 450 (15%) underwent surgery initiated laparoscopically. There was no difference in 3-year survival between patients undergoing laparoscopy [47.5%; 95% confidence interval (CI) 41.4-53.5] and laparotomy (52.6%; 95% CI 50.3-55.0; P=.12). Survival did not differ after adjustment for demographic characteristics, facility type, presence of comorbidities, and stage (adjusted hazard ratio, 1.09; 95% CI 0.93-1.28; P=.26). Postoperative hospitalization was slightly shorter in the laparoscopy group (median 4 compared with 5 days, P<.001). Frequency of readmission (5.3% compared with 3.7%; P=.26), death within 90 days of surgery (2.8% compared with 2.9%, P=.93), and suboptimal debulking (20.6% compared with 22.6%, P=.29) did not differ between patients undergoing laparoscopy and laparotomy. CONCLUSION: Ovarian cancer patients selected for laparoscopic interval debulking surgery after neoadjuvant chemotherapy have 3-year survival rates similar to women who undergo interval debulking by laparotomy. Laparoscopy is associated with a modestly shorter postoperative hospitalization, whereas readmission rates and risk of perioperative death are similar for the surgeries.
引用
收藏
页码:861 / 869
页数:9
相关论文
共 16 条
[1]   Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study [J].
Alletti, Salvatore Gueli ;
Bottoni, Carolina ;
Fanfani, Francesco ;
Gallotta, Valerio ;
Chiantera, Vito ;
Costantini, Barbara ;
Cosentino, Francesco ;
Ercoli, Alfredo ;
Scambia, Giovanni ;
Fagotti, Anna .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (04) :503.e1-503.e6
[2]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[3]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[4]   Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy [J].
Corrado, Giacomo ;
Mancini, Emanuela ;
Cutillo, Giuseppe ;
Baiocco, Ermelinda ;
Vici, Patrizia ;
Sergi, Domenico ;
Patrizi, Lodovico ;
Saltari, Maria ;
Baffa, Alberto ;
Vizza, Enrico .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (07) :1253-1257
[5]   POWER AND SAMPLE-SIZE CALCULATIONS - A REVIEW AND COMPUTER-PROGRAM [J].
DUPONT, WD ;
PLUMMER, WD .
CONTROLLED CLINICAL TRIALS, 1990, 11 (02) :116-128
[6]  
Edge SB., 2009, AJCC cancer staging manual, V7th
[7]   Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy [J].
Favero, Giovanni ;
Macerox, Nathalia ;
Pfiffer, Tatiana ;
Koehler, Christhardt ;
Miranda, Vanessa da Costa ;
Estevez Diz, Maria Del Pilar ;
Fukushima, Julia Tizue ;
Baracat, Edmund Chada ;
Carvalho, Jesus Paula .
ONCOLOGY, 2015, 89 (03) :159-166
[8]   Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial [J].
Kehoe, Sean ;
Hook, Jane ;
Nankivell, Matthew ;
Jayson, Gordon C. ;
Kitchener, Henry ;
Lopes, Tito ;
Luesley, David ;
Perren, Timothy ;
Bannoo, Selina ;
Mascarenhas, Monica ;
Dobbs, Stephen ;
Essapen, Sharadah ;
Twigg, Jeremy ;
Herod, Jonathan ;
McCluggage, Glenn ;
Parmar, Mahesh ;
Swart, Ann-Marie .
LANCET, 2015, 386 (9990) :249-257
[9]   Development of a comorbidity index using physician claims data [J].
Klabunde, CN ;
Potosky, AL ;
Legler, JM ;
Warren, JL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2000, 53 (12) :1258-1267
[10]   Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States [J].
Melamed, Alexander ;
Hinchcliff, Emily M. ;
Clemmer, Joel T. ;
Bregar, Amy J. ;
Uppal, Shitanshu ;
Bostock, Ian ;
Schorge, John O. ;
del Carmen, Marcela G. ;
Rauh-Hain, J. Alejandro .
GYNECOLOGIC ONCOLOGY, 2016, 143 (02) :236-240